Literature DB >> 27538606

Pain in patients with transverse myelitis and its relationship to aquaporin 4 antibody status.

Yazhuo Kong1, Helen Okoruwa2, Jon Revis2, George Tackley1, Maria Isabel Leite2, Michael Lee1, Irene Tracey1, Jacqueline Palace3.   

Abstract

Pain in transverse myelitis has been poorly studied. The aim of the study was to investigate the relationship between transverse myelitis related pain and disability, quality of life, anxiety and depression, cognitive-affective states in neuromyelitis optica (NMO) patients and aquaporin4 antibody status (AQP4-Ab +ve as positive and AQP4-Ab -ve as negative). Transverse myelitis patients (44 in total; 29 AQP4-Ab +ve and 15 AQP4-Ab -ve) completed questionnaires including Pain Severity Index (PSI), Pain Catastrophising Scale (PCS), Hospital Anxiety and Depression Scale (HADS), Short Form-36 quality of life (SF-36 QOL). Clinical details such as disability, gender, age and spinal cord lesion type (short or long lesion) were noted. Correlation and multiple linear regression tests were performed using these clinical scores. Pain was found to be correlated strongly with quality of life in both groups but only correlated with disability in the AQP4-Ab +ve group. PCS, HADS and EDMUS were found to be highly correlated with pain severity using partial correlation, however, a stronger relationship between pain severity and PCS was found in the AQP4-Ab -ve group. Multiple regression analysis showed that pain severity was the most important factor for quality of life but not disability or anxiety and depression symptoms in the whole patient group. We confirm that pain is an important symptom of transverse myelitis and has more influence on quality of life than disability despite health services being predominantly focused on the latter. There may be different factors associated with pain between AQP4-Ab +ve and -ve patients.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aquaporin-4 antibodies; Neuromyelitis optica; Neuropathic pain; Quality of life; Transverse myelitis

Mesh:

Substances:

Year:  2016        PMID: 27538606     DOI: 10.1016/j.jns.2016.06.041

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

1.  [Pain in multiple sclerosis and neuromyelitis optica spectrum disorders].

Authors:  Hannah L Pellkofer; Tania Kümpfel
Journal:  Schmerz       Date:  2021-05-25       Impact factor: 1.107

2.  Seronegative neuromyelitis optica spectrum disorder: severe polysymptomatic presentation with successful treatment response.

Authors:  Gilberto Pires da Rosa; Francisca Costa; Joana Guimarães; Fernando Friões
Journal:  BMJ Case Rep       Date:  2019-03-16

3.  Scrambler therapy improves pain in neuromyelitis optica: A randomized controlled trial.

Authors:  Maureen A Mealy; Sharon L Kozachik; Lawrence J Cook; Lauren Totonis; Ruth Andrea Salazar; Jerilyn K Allen; Marie T Nolan; Thomas J Smith; Michael Levy
Journal:  Neurology       Date:  2020-04-08       Impact factor: 9.910

4.  Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life.

Authors:  Jin Myoung Seok; Misong Choi; Eun Bin Cho; Hye Lim Lee; Byoung Joon Kim; Kwang Ho Lee; Pamela Song; Eun Yeon Joo; Ju-Hong Min
Journal:  PLoS One       Date:  2017-05-23       Impact factor: 3.240

5.  Co-administration of human adipose-derived stem cells and low-level laser to alleviate neuropathic pain after experimental spinal cord injury.

Authors:  Arash Sarveazad; Atousa Janzadeh; Gholamreza Taheripak; Sima Dameni; Mahmoud Yousefifard; Farinaz Nasirinezhad
Journal:  Stem Cell Res Ther       Date:  2019-06-24       Impact factor: 6.832

Review 6.  Interleukin-6: evolving role in the management of neuropathic pain in neuroimmunological disorders.

Authors:  Kenichi Serizawa; Haruna Tomizawa-Shinohara; Shota Miyake; Kenji Yogo; Yoshihiro Matsumoto
Journal:  Inflamm Regen       Date:  2021-11-02

7.  The risk factors of neuropathic pain in neuromyelitis optica spectrum disorder: a retrospective case-cohort study.

Authors:  Xiaojun Li; Haoyou Xu; Min Zhao; Yuanqi Zhao; Zequan Zheng; Huiying Ouyang; Guixian Chen; Zhenzhen Lou; Haoxuan Chen; Jiahui Zhang; Yibo Zhan; Hui Mao; Changlin Zhang
Journal:  BMC Neurol       Date:  2022-08-19       Impact factor: 2.903

Review 8.  Complexity and wide range of neuromyelitis optica spectrum disorders: more than typical manifestations.

Authors:  Jinming Han; Meng-Ge Yang; Jie Zhu; Tao Jin
Journal:  Neuropsychiatr Dis Treat       Date:  2017-10-20       Impact factor: 2.570

9.  Factors associated with fatigue in CNS inflammatory diseases with AQP4 and MOG antibodies.

Authors:  Tianrong Yeo; Giordani Rodrigues Dos Passos; Louwai Muhammed; Rosie Everett; Sandra Reeve; Silvia Messina; Fay Probert; Maria Isabel Leite; Jacqueline Palace
Journal:  Ann Clin Transl Neurol       Date:  2020-03-18       Impact factor: 4.511

10.  Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder: A Cross-Sectional Study of 166 AQP4 Antibody-Seropositive Patients.

Authors:  Ilya Ayzenberg; Daniel Richter; Eugenia Henke; Susanna Asseyer; Friedemann Paul; Corinna Trebst; Martin W Hümmert; Joachim Havla; Tania Kümpfel; Marius Ringelstein; Orhan Aktas; Brigitte Wildemann; Sven Jarius; Vivien Häußler; Jan-Patrick Stellmann; Makbule Senel; Luisa Klotz; Hannah L Pellkofer; Martin S Weber; Marc Pawlitzki; Paulus S Rommer; Achim Berthele; Klaus-Dieter Wernecke; Kerstin Hellwig; Ralf Gold; Ingo Kleiter
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-04-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.